Upon successful screening and registration, enrollment to durvalumab monotherapy (cohort 1) will begin. If DLT criteria are exceeded with durvalumab monotherapy (cohort 1), the study will close. Provided the safety of durvalumab monotherapy is established, enrollment to durvalumab plus BCG (cohort 2a) and durvalumab plus external beam radiation therapy (cohort 2b) will proceed.